Clinical trials in Potsdam – page 61

1 819 clinical trials in Potsdam, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Potsdam at a glance

1 819

clinical trials

Research sites1

Quick filters

1 819 trials in Potsdam

Open in trial search

Narcolepsy

Not yet recruiting

A Randomized, Double‑Blind Study of ORX750 versus Placebo for Excessive Daytime Sleepiness in Adults with Narcolepsy (Type 1 and Type 2)

Investigational

A Randomized, Double‑Blind Study of ORX750 versus Placebo for Excessive Daytime Sleepiness in Adults with Narcolepsy (Type 1 and Type 2)

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:ORX750
Sponsor:Centessa Pharmaceuticals UK Limited

Contact Research Centre

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug

Germany

Participants:18–64 years
Substances:Colestyramine
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Vividion Therapeutics Inc.

Contact Research Centre

Angina pectoris

Not yet recruiting

Study of Sublingual Glyceryl Trinitrate Spray to Reduce Angina in Adults with Symptomatic Coronary Artery Disease

Registered drug

Study of Sublingual Glyceryl Trinitrate Spray to Reduce Angina in Adults with Symptomatic Coronary Artery Disease

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Glyceryl Trinitrate
Sponsor:G. Pohl-Boskamp GmbH & Co. KG

Contact Research Centre

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Angelman's syndrome

Not yet recruiting

Study of the safety and efficacy of intrathecal rugonersen sodium in children and adults with Angelman syndrome

InvestigationalNo placebo

Study of the safety and efficacy of intrathecal rugonersen sodium in children and adults with Angelman syndrome

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years
Sponsor:Ohb Pediatrics Limited

Contact Research Centre

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Ruxolitinib
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Conjunctivitis allergic+1

Not yet recruiting

Diagnostic Accuracy of Parietaria judaica Pollen Extract (SPT‑RX) in a Skin Prick Test Drug Combination for Adults with Allergic Rhinitis and Controlled Mild Asthma

InvestigationalNo placebo

Diagnostic Accuracy of Parietaria judaica Pollen Extract (SPT‑RX) in a Skin Prick Test Drug Combination for Adults with Allergic Rhinitis and Controlled Mild Asthma

InvestigationalNo placebo

Germany

Participants:18–64 years
Substances:Phleum Pratense Pollen Extract
Sponsor:ROXALL Medizin GmbH

Contact Research Centre

Psychotic disorder+2

Not yet recruiting

A Randomized Controlled Trial of Cannabidiol vs Placebo Augmentation in Patients with First Episode Psychosis

Registered drug

A Randomized Controlled Trial of Cannabidiol vs Placebo Augmentation in Patients with First Episode Psychosis

Registered drug

Germany

Participants:18–64 years
Substances:Cannabidiol
Sponsor:University Of Oxford

Contact Research Centre

Influenza

Not yet recruiting

A Phase 3 Study of Efitazanamivir Alfa for Preventing Influenza in Adults and Adolescents at High Risk of Complications

Investigational

A Phase 3 Study of Efitazanamivir Alfa for Preventing Influenza in Adults and Adolescents at High Risk of Complications

Investigational

Germany

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Cidara Therapeutics Inc.

Contact Research Centre

Complicated fracture

Not yet recruiting

A study of local iloprost therapy to improve bone healing in patients with high‑risk fractures

Registered drug

A study of local iloprost therapy to improve bone healing in patients with high‑risk fractures

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Charite Universitaetsmedizin Berlin KöR

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Potsdam

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer treatments, including studies for triple-negative, HER2-positive, and hormone receptor-positive variants. Research encompasses new combination therapies and targeted treatments.

Early-stage breast cancer interventions
HPV-positive oropharyngeal cancer treatments
Advanced treatment strategies

Multiple studies are evaluating novel drug combinations and personalized therapeutic approaches.

02 Dermatological Studies

Clinical research targeting various skin conditions, including atopic dermatitis and chronic skin disorders. Studies focus on both topical and systemic treatments.

Actinic keratosis treatments
Hidradenitis suppurativa therapy
Plaque psoriasis management

Investigations include both traditional and innovative therapeutic approaches for skin conditions.

03 Neurological Research

Studies focusing on multiple sclerosis treatment options, evaluating new medications and comparing their effectiveness to existing therapies.

Relapsing-remitting MS treatments
Novel therapeutic approaches
Disease modification strategies

Research aims to improve treatment outcomes and quality of life for patients with neurological conditions.

04 Cardiovascular Studies

Research focusing on cardiovascular disease management and innovative treatments for related conditions, including studies on lipid management.

Lipoprotein management
Cholesterol reduction therapies
Cardiovascular risk prevention

Trials aim to reduce major cardiovascular events and improve patient outcomes.

Back to Germany All countries